Acta Scientific Nutritional Health (ASNH)(ISSN: 2582-1423)

Research Article Volume 4 Issue 1

Implementation of the HIV Test-and-Treat Strategy in PEPFAR Supported Health Facilities in Yaoundé-Cameroon: Antiretroviral Side Effects, Retention and Viral Load Suppression Outcomes

R Medang1*, C Ayangma2, A Elang1, M Eya4, M Dieffi1 and A Socpa3

1Metabiota, Cameroon
2Military Hospital Yaoundé, Cameroon
3Yaoundé University, Cameroon
4High School of Teacher’s Training, Cameroon

*Corresponding Author: R Medang, Project Manager, Metabiota, Cameroon.

Received: October 14, 2019; Published: December 17, 2019

×

Abstract

Introduction:The test-and-treat strategy related to HIV, seems to have yielded inconsistent results in Cameroon. We explored how biomedical aspects and side effects related to HIV first-line ART regimen might impact adherence to treatment, and overall outcomes of HIV infected individuals, within the test-and-treat strategy in Cameroon.

Methods: We conducted a qualitative and quantitative study with PLHIV. BMI values, liver and kidney related lab examinations were determined at inclusion and 6 months later, including VL. Follow up information were collected on a monthly basis. FGD sessions were carried out and analyzed by Atlas Ti 6.2.

Results: 155 PLHIV were included, and contributed 423 person-months of follow-up. TDF/3TC/EFV was prescribed to 63 participants (40.6%; - CI95%: 32.8% - 48.8%) at inclusion, whereas 92 received TDF/FTC+EFV at inclusion (59.4%; - CI95%: 51.2% - 67.2%), as first line treatment (p = 0.02144). 9 participants died during the study (CMR: 5.8%). Out of 930 expected follow up visits, 346 (37.2%; [CI95%: 34.1% - 40.4%]) occurred. 31 participants received their viral load results, and 93.5% were virally suppressed. Being a female (AOR = 3.05, 95%CI: 1.65 – 7.36), adhering to ART (AOR=2.05, 95% CI: 1.21 – 5.24) and not experiencing any side effects (AOR = 2.15, 95%CI: 1.25 – 5.66) were significantly associated with suppressed VL. Also being a male (AOR = 3.01, 95%CI: 1.25 – 6.34), having high levels of creatinine at initiation (AOR=2.01, 95% CI: 1.69 – 6.32), not adhering to ART (AOR=3.50, 95% CI: 1.98 - 7.01) and receiving treatment in district hospital biyemassi (AOR = 2.21, 95%CI: 1.69 – 7.36) were significantly associated with mortality. Under the qualitative component, 76 codes, 07 themes and 16 subthemes were identified. Among the themes identified were the limiting factors/enabling environment, overall perceptions, skills development, denial, missed appointments and other considerations in relation to PLHIV and ARVs, and side effects.

Conclusion: Poor retention in ART treatment continues to be the main issue in the implementation of the test-and-treat strategy. Occurrence of side effects, poor communication between service providers and PLVIH, as well as lack of therapeutic education, were identified as being some of the root causes of poor retention and adherence to ART.

Keywords: HIV; Test-and-Treat; ARV; Side Effects; Adherence; Viral Load

×

References

  1. Adelekan Babatunde., et al. “Social Barriers in Accessing Care by Clients Who Returned to HIV Care after Transient Loss to Follow-Up”. AIDS Research and Therapy 16 (2019).
  2. Constance Enongene-Kome., et al. “Community Participation in the Retention of Adults in HIV Care in the Muyuka Health District, South-West Region, Cameroon”. The Pan African Medical Journal 33 (2019): 32.
  3. Cooper David A., et al. “Efficacy and Safety of Maraviroc vs. Efavirenz in Treatment-Naive Patients with HIV-1: 5-Year Findings”. AIDS (London, England) 28.5 (2014): 717-725. 
  4. Eshun-Wilson Ingrid., et al. “Being HIV Positive and Staying on Antiretroviral Therapy in Africa: A Qualitative Systematic Review and Theoretical Model”. PloS One 14.1 (2019): e0210408.
  5. Gallant Joel E., et al. “Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial”. JAMA 292.2 (2004): 191-201.
  6. Gardner Edward M., et al. “The Spectrum of Engagement in HIV Care and Its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection”. Clinical Infectious Diseases 52.6 (2011): 793-800.
  7. Holtzman Carol W., et al. “Mapping Patient-Identified Barriers and Facilitators to Retention in HIV Care and Antiretroviral Therapy Adherence to Andersen’s Behavioral Model”. AIDS Care 27.7 (2015): 817-828.
  8. Horter Shona., et al. “‘Life Is so Easy on ART, Once You Accept It’: Acceptance, Denial and Linkage to HIV Care in Shiselweni, Swaziland”. Social Science and Medicine 176 (2017): 52-59.
  9. Jose, Sophie., et al. “A Continuum of HIV Care Describing Mortality and Loss to Follow-up: A Longitudinal Cohort Study”. The Lancet. HIV 5.6 (2018): e301-308.
  10. Jotwani Vasantha., et al. “Association of HIV Infection with Biomarkers of Kidney Injury and Fibrosis in the Multicenter AIDS Cohort Study”. Antiviral Therapy 22.5 (2017): 421-429.
  11. Levison Julie H., et al. “‘Where It Falls Apart’: Barriers to Retention in HIV Care in Latino Immigrants and Migrants”. AIDS Patient Care and STDs 31.9 (2017): 394-405.
  12. MacCarthy Sarah., et al. “‘How Am I Going to Live?’: Exploring Barriers to ART Adherence among Adolescents and Young Adults Living with HIV in Uganda”. BMC Public Health 18 (2018).
  13. Ministere de la Santé Publique. Guide national de prise en charge des personnes vivant avec le VIH/SIDA − Cameroun (2015).
  14. Nsanzimana Sabin., et al. “Retention in Care and Virological Failure among Adult HIV+ Patients on Second-Line ART in Rwanda: A National Representative Study”. BMC Infectious Diseases 19.1 (2019): 312.
  15. Palfai Tibor P., et al. “Development of a Tailored, Telehealth Intervention to Address Chronic Pain and Heavy Drinking among People with HIV Infection: Integrating Perspectives of Patients in HIV Care”. Addiction Science and Clinical Practice 14 (2019).
  16. Penda Calixte Ida., et al. “Feasibility and Utility of Active Case Finding of HIV-Infected Children and Adolescents by Provider-Initiated Testing and Counselling: Evidence from the Laquintinie Hospital in Douala, Cameroon”. BMC Pediatrics 18 (2018). 
  17. Segamwenge Innocent Lule and Miriam Kaunanele Bernard. “Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy”. Case Reports in Hepatology (2018): 1270716.
  18. Shet Anita., et al. “Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort”. Current HIV Research 14.1 (2016): 71-79.
  19. Stern Erin., et al. “Conceptions of Agency and Constraint for HIV-Positive Patients and Healthcare Workers to Support Long-Term Engagement with Antiretroviral Therapy Care in Khayelitsha, South Africa”. African Journal of AIDS Research: AJAR 16.1 (2017): 19-29.
  20. Suzuki Soichiro., et al. “Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort”. AIDS Patient Care and STDs 31.3 (2017): 105-112.
  21. Tang Houlin., et al. “‘Late for Testing, Early for Antiretroviral Therapy, Less Likely to Die’: Results from a Large HIV Cohort Study in China, 2006-2014”. BMC Infectious Diseases 18.1 (2018): 272.
  22. Taramasso L., et al. “First-Line Antiretroviral Therapy with Efavirenz plus Tenofovir Disiproxil Fumarate/Emtricitabine or Rilpivirine plus Tenofovir Disiproxil Fumarate/Emtricitabine: A Durability Comparison”. HIV Medicine (2018).
  23. Tetteh Raymond A., et al. “Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients”. Drug Safety 39.11 (2016): 1139-1149.
  24. Tsague, Landry., et al. “Determinants of Retention in Care in an Antiretroviral Therapy (ART) Program in Urban Cameroon, 2003-2005”. The Pan African Medical Journal 1 (2008): 2.
  25. UNAIDS. 90-90-90 An Ambitious Treatment Target to Help End the AIDS Epidemic. UNAIDS (2014).
  26. Van Cutsem Gilles., et al. “Correcting for Mortality Among Patients Lost to Follow Up on Antiretroviral Therapy in South Africa: A Cohort Analysis”. PLoS ONE 6.2 (2011).
  27. Venkatesh Kartik K., et al. “Who Gets Tested for HIV in a South African Urban Township? Implications for Test and Treat and Gender-Based Prevention Interventions”. Journal of Acquired Immune Deficiency Syndromes 56.2 (2011): 151-165.
  28. Wagner Bradley G., et al. “Should We Try to Eliminate HIV Epidemics by Using a ‘Test and Treat’ Strategy?” AIDS (London, England) 24.5 (2010): 775-76.
  29. OMS. ‘’Traiter Toutes Les Personnes Vivant Avec Le VIH”. (2015).
  30. Young J., et al. “The Rate of Recovery in Renal Function When Patients with HIV Infection Discontinue Treatment with Tenofovir”. HIV Medicine 15.8 (2014): 505-510.
  31. Zucker Jason., et al. “Predictors of Disengagement in Care for Individuals Receiving Pre-Exposure Prophylaxis (PrEP)”. Journal of Acquired Immune Deficiency Syndromes 81.4 (2019): e104-108.
×

Citation

Citation: R Medang., et al. “Implementation of the HIV Test-and-Treat Strategy in PEPFAR Supported Health Facilities in Yaoundé-Cameroon: Antiretroviral Side Effects, Retention and Viral Load Suppression Outcomes".Acta Scientific Nutritional Health 4.1 (2020): 96-124.



Member In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for March Issue
    The last date for submission of articles for regular Issues is February 29, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US